The Schall Law Firm is investigating Qiagen N.V. for potential securities law violations after the company gave conflicting guidance on its QuantiFERON product's growth. In February 2026, Qiagen forecasted 6-7% growth for QuantiFERON, but by April, the CFO revised this, projecting sales to remain flat through 2026 and only normalize growth in 2027. This discrepancy has prompted a shareholder fraud investigation, and affected investors are encouraged to contact the law firm for potential legal action. The case highlights risks of misleading corporate forecasts impacting investor decisions.
Emerson Electric announced a collaboration with Saudi Aramco to co-develop next-generation corrosion management solutions using ultrasonic online monitoring and wireless technology. This partnership aims to improve operational safety and performance ...
Natural Grocers, a leading organic grocery retailer, is opening its first store in Wisconsin on June 10, 2026, in Lake Geneva. The grand opening will feature giveaways, discounts, a prize wheel, and a $2,500 donation to the Lake Geneva Food Pantry, h...
Current inflation trends in the U.S. are often compared to the 1970s stagflation, but experts highlight key differences. Unlike the 1970s, today's inflation is driven mainly by supply-side pressures such as rising commodity prices and geopolitical te...
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, announced it will present at two upcoming investor conferences: William Blair’s Growth Stock Conference on June 2 and Jefferies Global Healthcare Conf...
